


FRONT LINE COVID-19 CRITICAL CARE ALLIANCE PROPHYLAXIS & TREATMENT PROTOCOLS FOR COVID-19

# COVID-19: Ivermectin and the TRUTH




## Paul Marik MD, FCCM, FCCP

# The Vacuum of Truth





# A Global Disaster






# **Treatment: Focus on IVERMECTIN**

- William Campbell and Satoshi Omura awarded Nobel Prize in 2015 for their 1975 discovery of Ivermectin
- Ivermectin was first used in humans in 1987
- Binds selectively to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells
- Ivermectin is highly lipophilic, rapidly absorbed (Tmax = 4 hours), plasma T  $\frac{1}{2}$  16-28 hrs.
- On World Health Organization's (WHO) list of essential medicines
- Over the past three decades, approximately 3.7 billion doses of ivermectin have been distributed
- Broad spectrum anti-parasitic and anti-viral activity
- Potent anti-inflammatory and immune modulating effects
- Safe and well tolerated in humans up to 2000 ug/kg. Minor side effects include pruritis, fever, rash, arthralgia

# Nobel Lecture of Prof. Satoshi Omura



# Nobel Lecture of Prof. Satoshi Omura





Check for updates


# Elucidation of the inhibitory activity of ivermectin with host nuclear importin $\alpha$ and several SARS-CoV-2 targets

#### Martiniano Bello 💿

Laboratorio de Diseño y Desarrollo de Nuevos Fármacos e Innovación Biotecnológica de la Escuela Superior de Medicina, Instituto Politécnico Nacional, Ciudad de Mexico, Mexico

System	$\Delta E_{vdw}$
Importin-α-IVM	-40.54 (5.3)
Nsp9-IVM	-41.03 (4.2)
RdRp-IVM	-37.89 (4.9)
RBD-spike-IVM	-36.59 (3.4)
3CL <sup>pro</sup> -sub1-IVM	-57.74 (7.6)
3CL <sup>pro</sup> -sub2-IVM	-50.75 (3.6)

# Ivermectin inhibits SARS-CoV-2 in vitro



# Relevance of IC<sub>50</sub> determined *in vitro* to clinical use?

- In vitro assay very different from clinical situation
  - Vero/hSLAM cells- monkey kidneydo not produce IFN
  - Lack immune responses
- Ivermectin accumulates in lungs and other tissues (3x-10x serum levels)
- Human lung cells- better IC<sub>50</sub>
- Short exposure vs extended exposure
- Single dose vs repeat dosing
- Taken with food (3x level)

Red- peer-reviewed, published modelling of IVM lung concentration after 200ug/kg dose

Reproduced with Permission from Wagstaff et al; Unpublished data 2021

# Pharmacology

- 400ug/kg Cmax ~ 120 ug/ml (fasted)
- 400ug/kg Cmax about 300 ug/ml (with meal)
- 400ug/kg Lung concentration 360 ug/g tissue (fasted)
- 400ug/kg Lung concentration 900 ug/g tissue (with meal)
- IC<sub>50</sub> for alveolar cells 0.41 uM (307 ug/g) (uM to ng/ml conversion: 1uM = 750 ng/ml)

# SCHEST<sup>®</sup> JOURNAL

# Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVID-19 (ICON study) Juliana Cepelowicz Rajter, M.D., Michael S. Sherman, M.D., FCCP, Naaz Fatteh,

M.D., Fabio Vogel, Pharm. D, BCPS, Jamie Sacks, Pharm. D., Jean-Jacques Rajter,


RESULT		2	I CI	OR	
15%	25.21	0.03	0.29-0.96	1.52	
		0.001	0.05-0.47	0-15	
		0.07	0.88-11.00	3.11	
OR	0.27	0.03	0.09 - 0.80	0.27	
	15%. 38-8%. 36-1%.	15%. 25.2%. 38-8%. 80.7%. 36.1%. 15.4%.	15%. 25.2%. 0.03 38.8%. 80.7%. 0.001 36.1%. 15.4%. 0.07	15%. 25.27. 0.03 0.29-0.96   38.8%. 80.7%. 0.001 0.05-0.47   36.1%. 15.4%. 0.07 0.88 - 11.00	



### Annales de Dermatologie et de Vénéréologie



Volume 147, Issue 12, Supplement, December 2020, Page A194



Long term Care Facility A

Long term Care Facility B+C+D

## **IVERMECTIN FOR COVID-19** 71 TRIALS, 675 SCIENTISTS, 50,180 PATIENTS **31 RANDOMIZED CONTROLLED TRIALS** 83% IMPROVEMENT IN 16 PROPHYLAXIS TRIALS RR 0.17 [0.11-0.27] 66% IMPROVEMENT IN 29 EARLY TREATMENT TRIALS RR 0.34 [0.24-0.47] 34% IMPROVEMENT IN 26 LATE TREATMENT TRIALS RR 0.66 [0.53-0.81] 52% IMPROVEMENT IN 32 MORTALITY RESULTS RR 0.48 [0.37-0.63] 57% IMPROVEMENT IN 31 RANDOMIZED CONTROLLED TRIALS RR 0.43 [0.31-0.61] SUMMARY OF RESULTS REPORTED IN IVERMECTIN TRIALS FOR COVID-19, 12/24/21, IVMMETA.COM



## Network meta-analysis of interventions on hospital mortality

## meta Evidence - COVID-19

Living meta-analysis and evidence synthesis of therapies for COVID19

	noteworthy treatments 👻	cov	ID 19 ho	spitalized	<b>i</b> •	All RCTs	✓ deaths	•
Trea	tment			: other Effects			R 95%	-CI
ivern	nectin			—		0.6	62 [0.40; 0.	95]
cortic	costeroids			-		0.8	35 [0.76; 0.	95]
sarilu	ımab					0.7	78 [0.47; 1.	29
remo	lesivir			<del></del>			36 [0.70; 1.	-
tocili	zumab			-+-			3 [0.80; 1.	
conv	alescent plasma treatment			<b>→</b>			94 [0.81; 1.	
	eron			<u> </u>			6 [0.76; 1.	
colch	nicine			+			01 [0.87; 1.	-
contr	ol					1.0		
	oxychloroquine		1	+	-		02 [0.88; 1.	18]
	(	0.2	0.5	1	2	5		

Tweets	Tweets & replies	Media	Likes
	🤣 @US_FDA · 9h	0	
	ot a horse. You are not a cow.	Seriousiy, y all. Stop	
	- P		

## Horowitz: FDA disseminates dangerous and libelous misinformation against lifesaving COVID treatment

DANIEL HOROWITZ | August 23, 2021



f 🍠 in 🖾

VigiAccess™	Uppsala Monitoring Centre WHO Collaborating Centre for International Drug Monitoring					
Medicine	Year started reporting	Deaths	Adverse events			
Ivermectin	1992	18	4 669			
Remdesivir	2020	579	7 798			
Tocilizumab	2005	786	47 345			
COVID-19 vaccines	2021	13 361	2 620 423			
Tetanus vaccine	1968	32	14 697			
Measles vaccine	1992	35	3 696			
Acetaminophen (Tylenol)	1968	3 865	> 146 000			







Over 25 Years of Clinical Experience With Ivermectin: An Overview of Safety for an Increasing Number of Indications

- Cannot be used in collie dogs due to increased BB permeability to Ivermectin
- Negligible adverse reaction in humans
- Not a single death directly related to IVERMECTIN
- Robust safety profile, can be used in children ad young as 6 months of age
- Allergic reaction due to the death of microfilaria (itching, rash)
- Encephalopathy, rarely in patients with Loa Loa
- Not recommended in pregnancy or lactation
- Drug-drug interactions, caution with calcineurin inhibitors


Kircik LH et al. J Drugs Dermatol 2016;5 325



Tokyo Medical Chairman holds press conference recommending Ivermectin to all doctors, for all Covid patients. Japan's government is one of the most conservative and cautious in the world. The data is clear.

## 22<sup>nd</sup> August 2021

# COVID-19 in Tokyo Japan



On August 13 <u>Tokyo Medical Association</u> announced that **Ivermectin** is amazingly effective at stopping COVID-19.

They recommend to ALL Doctors in Japan using Ivermectin to treat COVID.

#### ICMR Includes Ivermectin for COVID-19 Indication in National List of Essential Medicines



TrialSite Staff September 5, 2021


🗐 6 Comments



The Indian government recently slashed the price of 39 important drugs covering a range of therapeutic drugs from cancer to COVID-19 as part of the revised Indian National List of Essential Medicines (NLEM). TrialSite reports among the commonly used drugs prominently on the list are ivermectin indicated for SARS-CoV-2, the virus

## Ivermectin obliterates 97 percent of Delhi cases

By Justus R. Hope, MD Jun 1, 2021 Updated Jun 7, 2021 🔍 24



#### f 🎔 🗖 🔂 🗋

A 97% decline in Delhi cases with Ivermectin is decisive - period. It represents the last word in an epic struggle to save lives and preserve human rights. This graph symbolizes the victory of reason over corruption, good over evil, and right over wrong. It is as significant as David's victory over Goliath. It is an absolute vindication of Ivermectin and early outpatient treatment. It is a clear refutation of the WHO, FDA, NIH, and CDC's policies of "wait at home until you turn blue" before you get treatment.



Plot 50161, Block 5, Gaborone, Building 6, Section 20, Unit 4, Grand Park Business Centre P O Box 21815, Bontleng, Gaborone infolibdu.org.bw Office: 395 2512 Cell; 73 278 074

01/09/2021

#### PRESS RELEASE

#### To: All Media Houses

#### URGENT PRESS RELEASE ON THE USE OF IVERMECTIN FOR COVID-19


As the recent Covid-19 wave wanes, the Botswana Doctors Union would like to share its professional views on the medical and clinical management of Covid-19 disease. We have resolved that due to Botswana's Covid-19 response and/or capacity to curb and respond, it would be prudent to incorporate all potentially beneficial treatment regimens in the management of moderate to severe disease regardless of vaccination status.

We have had several meetings with the panel of experts in the Botswana Covid-19 Ivermectin Intervention Group (BCIIG) and have studied the scientific data and rational views of their recommendations and those of others on the incorporation of Ivermectin in the management of Covid-19. We, therefore, wish to categorically state the following:

#### We, the Botswana Doctors Union are in full support of the safe prescribing and "off-label use" of Ivermectin in conjunction with other treatment agents in the management of Sars-Cov-2 disease for the following reasons:

- The evidence that supports the effectiveness of Ivermectin in the recovery of Sars-2-Cov patients is irrefutable and it is available.
- Safe and open prescribing practices by licensed clinicians help ensure appropriate drug stewardship and patient safety.
- Drug regulation, abuse, and adverse effects can be adequately monitored.
- In addition to vaccination efforts, alternative treatments can further serve to alleviate morbidity and prevent mortality.
- However small the impact may be, a life salvaged is a life saved, and that is significant.
- Human-dosed Ivermectin has a profound safety profile, which is unlikely to reach toxicity levels if used correctly.





# Remdesivir for treatment of COVID-19: Grouped By Pharma Controlled vs Independent


### Meta-analysis of Mortality

Group by	Study name		Statist	ics for e	ach stud	Y		Odds	ratio and	d 95% Cl	
Pharma/IND		Odds ratio	Lower limit	Upper limit	Z-Value	p-Value					
I	Wang	1.116	0.501	2.488	0.269	0.788			-+	-	
1	SOLIDARITY	0.978	0.826	1.159	-0.254	0.800			•		
1	VA Coperative	1.175	0.910	1.516	1.234	0.217			- <b>b</b>		
I	DisCoVery	0.866	0.475	1.581	-0.467	0.640			_ <b>-------------</b>		
1		1.027	0.897	1.176	0.391	0.696			•		
Р	Beigel	0.724	0.507	1.035	-1.773	0.076					
Р	Spinner	0.249	0.045	1.370	-1.599	0.110			<b>—</b>		
Р		0.692	0.488	0.982	-2.062	0.039			•		
Overall		0.976	0.860	1.107	-0.380	0.704					
							0.01	0.1	1	10	100
							F	avours Rem	d.	Favours Cont	trol

Meta Analysis


# **REMDESIVIR VS IVERMECTIN**

COMPARISONS	REMDESIVIR	IVERMECTIN
COST	\$ 3,000.00	PENNIES
LOWER DEATH RATE IN STUDIES	NO	YES 50% +
SIMPLE ACCESS AT HOME	NO	YES
CAUSES ORGAN DAMAGE	YES	NO
STUDIES NEEDED FOR APPROVAL	1 and approved	60 + and not considered
MAJOR CONFLICTS OF INTEREST	YES	NO
SUPPORT OF FDA AND FAUCI	YES	NO





# COVID-19 Misinformation...



# 66

The truth has no defense against a fool determined to believe a lie.

#### MARK TWAIN

